# A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients

> **NCT03317223** · PHASE3 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 350 (actual)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** CJ-12420/Clarithromycin/Amoxicillin

## Key facts

- **NCT ID:** NCT03317223
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-17
- **Primary completion:** 2019-01-21
- **Final completion:** 2019-01-24
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2021-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03317223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03317223, "A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03317223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*